Kestra Medical Technologies (KMTS) Earnings Analysis
Kestra Medical Technologies (KMTS) next reports earnings on 2026-09-10, consensus EPS -0.63 USD. Last quarter (2026-07-14) it missed with EPS -0.67 USD vs -0.59 USD est (-13.6%). It has beaten estimates in 1/5 recent quarters (20%). Trailing P/E -8.63.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does KMTS next report earnings?
| Next earnings date | 2026-09-10 |
|---|---|
| Consensus EPS estimate | -0.63 USD |
| Revenue estimate | 0.03B |
KMTS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-07-14 | -0.67 USD | -0.59 USD | -13.6% | Miss |
| 2026-03-17 | -0.61 USD | -0.6 USD | -1.7% | Miss |
| 2025-12-11 | -0.62 USD | -0.59411 USD | -4.4% | Miss |
| 2025-09-11 | -0.46 USD | -0.66 USD | +30.3% | Beat |
| 2025-07-17 | -1.05086 USD | n/a | n/a | n/a |
| 2025-04-14 | -1.25 USD | -0.60333 USD | -107.2% | Miss |
Beat rate: 1/5 (20%) over reported quarters with consensus data.
KMTS valuation and analyst view
| Trailing P/E | -8.63 |
|---|---|
| Trailing EPS | -2.25376 USD |
| Price / book | 4.70 |
| Dividend yield | 0.00% |
| Market cap | 1.25B |
| Analyst consensus | Buy (3 buy / 1 hold / 0 sell) |
| Avg price target | 31 USD |
Related research pages
Frequently asked questions
When is Kestra Medical Technologies (KMTS)'s next earnings date?
Kestra Medical Technologies is next scheduled to report on 2026-09-10, with a consensus EPS estimate of -0.63 USD and revenue estimate of 0.03B.
Did KMTS beat earnings last quarter?
In its 2026-07-14 report, KMTS posted EPS of -0.67 USD versus a -0.59 USD estimate — a miss of 13.6%.
What is KMTS's earnings track record?
Over the last 5 reported quarters with consensus data, KMTS beat estimates 1 times (20%).
What is KMTS's current P/E ratio and EPS?
KMTS trades at a trailing P/E of -8.63 on trailing EPS of -2.2537575669090057 USD.
What do analysts rate KMTS?
Analyst consensus is "Buy" across 4 ratings (0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 31 USD.